We offer a cost effective alternative to an Open Label Extension
Inceptua provides pharmaceutical companies with a cost-effective solution to ensure the ongoing provision of treatment for clinical trial participants once the trial ends, and until a medication becomes commercially available.
Following the completion of a clinical trial, pharmaceutical companies usually have a responsibility to maintain the supply of an investigational medicines to patients until it becomes available in the commercial market. Moreover, in cases where a drug doesn’t succeed in its clinical trial or the pharmaceutical company decides to halt its development, there might still be commitments to supply the trial medication to patients who have experienced clinical benefits. This often leads to the pharmaceutical companies to keep the clinical trial sites open which carries an ongoing expense and allocation of internal resources.
Inceptua provides pharmaceutical companies with a cost effective option to bridge the treatment gap for trial patients until the medication is commercially available, or until the patients have completed their treatment.
Why Inceptua:
1. One single, trusted partner to continue the supply of medicines from your clinical trial to patients once the trial has come to an end and up to the point of commercial availability
2. Asset-specific Program Strategy – Successful programs (300+ programs) devised through deep Early Access and commercial pharma experience to develop Post Trial Supply strategies to synergize with your strategic decisions
3. Global Competence – Global coverage for your program in more than 120 markets worldwide, with deep experience in complex markets
4. Industry Thought-Leaders – Pioneering team in the Early Access world, having developed industry standard services means you receive industry-best guidance, adapting to external developments in real-time to ensure optimal program performance
Ask our experts
About
About
About
About
